{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:03:08Z","timestamp":1788825788440,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01436-9","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:45:09Z","timestamp":1747197909000},"page":"2031-2045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Demographics, Clinical Characteristics, and Treatment Patterns in Patients with Psoriasis: Insights from the Saudi Arabia Psoriasis Registry (PSORSA)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-0595","authenticated-orcid":false,"given":"Mohammad Ibrahim","family":"Fatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-7102","authenticated-orcid":false,"given":"Yousef","family":"Binamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0985-6193","authenticated-orcid":false,"given":"Hajer Y.","family":"Almudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-6143","authenticated-orcid":false,"given":"Maysa Tariq","family":"Eshmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3824-9537","authenticated-orcid":false,"given":"Fawaz Hamdi","family":"Aljehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5186-6961","authenticated-orcid":false,"given":"Sultanah","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-9086","authenticated-orcid":false,"given":"Ahmed H.","family":"Al-Jedai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"1436_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475.","journal-title":"Int J Mol Sci"},{"key":"1436_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1172\/JCI200422147","volume":"113","author":"BJ Nickoloff","year":"2004","unstructured":"Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664.","journal-title":"J Clin Invest"},{"key":"1436_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/CCID.S352654","volume":"15","author":"F Alzeer","year":"2022","unstructured":"Alzeer F, Alotair H, Aleisa A. Epidemiology and cutaneous manifestations of psoriasis in Saudi Arabia: a narrative review. Clin Cosmet Investig Dermatol. 2022;15:347\u201355.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1436_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263\u201371.","journal-title":"Lancet"},{"key":"1436_CR5","doi-asserted-by":"crossref","unstructured":"Hepat A, Chakole S, Rannaware A, Hepat A, Chakole S, Rannaware A. Psychological well-being of adult psoriasis patients: a narrative review. Cureus. 2023;15:e37702.","DOI":"10.7759\/cureus.37702"},{"key":"1436_CR6","first-page":"891","volume":"146","author":"SK Kurd","year":"2010","unstructured":"Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891\u20135.","journal-title":"Arch Dermatol"},{"key":"1436_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.det.2008.11.013","volume":"27","author":"M Wakkee","year":"2009","unstructured":"Wakkee M, Nijsten T. Comorbidities in dermatology. Dermatol Clin. 2009;27:137\u201347.","journal-title":"Dermatol Clin"},{"key":"1436_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","volume":"149","author":"H Yeung","year":"2013","unstructured":"Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173\u20139.","journal-title":"JAMA Dermatol"},{"key":"1436_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","volume":"130","author":"BB Davidovici","year":"2010","unstructured":"Davidovici BB, Sattar N, J\u00f6rg PC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785\u201396.","journal-title":"J Invest Dermatol"},{"key":"1436_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","volume":"58","author":"AB Kimball","year":"2008","unstructured":"Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National psoriasis foundation clinical consensus on psoriasis co-morbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012. https:\/\/doi.org\/10.1161\/JAHA.113.000062.","journal-title":"Nutr Diabetes"},{"key":"1436_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.sder.2010.01.002","volume":"29","author":"N Kim","year":"2010","unstructured":"Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10\u20135.","journal-title":"Semin Cutan Med Surg"},{"issue":"Suppl","key":"1436_CR13","first-page":"2","volume":"13","author":"L Guenther","year":"2009","unstructured":"Guenther L, Gulliver W. Psoriasis comorbidities. J Cutan Med Surg. 2009;13(Suppl):2.","journal-title":"J Cutan Med Surg"},{"key":"1436_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000342180","volume":"225","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011. Dermatology. 2012;225:121\u20136.","journal-title":"Dermatology"},{"key":"1436_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1529-8019.2010.01312.x","volume":"23","author":"J Hayes","year":"2010","unstructured":"Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. Dermatol Ther. 2010;23:174\u201380.","journal-title":"Dermatol Ther"},{"key":"1436_CR16","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1080\/09546634.2021.1950601","volume":"33","author":"MIA Fatani","year":"2022","unstructured":"Fatani MIA, Hamadah IRA, Alajlan MA, Binamer Y, Alharbi AHS, Alruwaili AFS, et al. Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). J Dermatolog Treat. 2022;33:1916\u201330.","journal-title":"J Dermatolog Treat"},{"key":"1436_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000096196","volume":"213","author":"M Schmitt-Egenolf","year":"2006","unstructured":"Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology. 2006;213:327\u201330.","journal-title":"Dermatology"},{"key":"1436_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.blo.0000079325.41006.95","volume":"413","author":"A Hartz","year":"2003","unstructured":"Hartz A, Marsh JL. Methodologic issues in observational studies. Clin Orthop Relat Res. 2003;413:33\u201342.","journal-title":"Clin Orthop Relat Res"},{"key":"1436_CR19","first-page":"669","volume":"1","author":"RE Gliklich","year":"2014","unstructured":"Gliklich RE, Dreyer NA, Leavy MB. Registries for evaluating patient outcomes. AHRQ Publ. 2014;1:669.","journal-title":"AHRQ Publ"},{"key":"1436_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/exd.14770","volume":"32","author":"XY Teoh","year":"2023","unstructured":"Teoh XY, Suganthy R, Voo SYM, Tang MM. Pustular psoriasis in Malaysia: a review of the Malaysian psoriasis registry 2007\u20132018. Exp Dermatol. 2023;32:1253\u201362.","journal-title":"Exp Dermatol"},{"key":"1436_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ad.2010.10.016","volume":"102","author":"R Rivera","year":"2011","unstructured":"Rivera R, Garc\u00eda-Doval I, Carretero G, Daud\u00e9n E, S\u00e1nchez-Carazo J, Ferr\u00e1ndiz C, et al. BIOBADADERM, the Spanish registry of adverse events associated with biologic drugs in dermatology: first report. Actas Dermosifiliogr. 2011;102:132\u201341.","journal-title":"Actas Dermosifiliogr"},{"key":"1436_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjd.13343","volume":"172","author":"R Gniadecki","year":"2015","unstructured":"Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244\u201352.","journal-title":"Br J Dermatol"},{"key":"1436_CR23","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12:48\u201357.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1436_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bjd.13001","volume":"171","author":"SP Menting","year":"2014","unstructured":"Menting SP, Sitaram AS, Bonnerjee-Van Der Stok HM, De Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171:875\u201383.","journal-title":"Br J Dermatol"},{"key":"1436_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/09546634.2014.933166","volume":"26","author":"E Fonseca","year":"2015","unstructured":"Fonseca E, Iglesias R, Paradela S, Fern\u00e1ndez-Torres RM, Elberd\u00edn L. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting. J Dermatolog Treat. 2015;26:217\u201322.","journal-title":"J Dermatolog Treat"},{"key":"1436_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjd.12344","volume":"169","author":"I Garcia-Doval","year":"2013","unstructured":"Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol. 2013;169:710\u20134.","journal-title":"Br J Dermatol"},{"key":"1436_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jaad.2013.10.019","volume":"70","author":"S Piaserico","year":"2014","unstructured":"Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, MacCarone M, Picardo M, et al. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol. 2014;70:257-262.e3.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2133.2011.10396.x","volume":"165","author":"M Inzinger","year":"2011","unstructured":"Inzinger M, Heschl B, Weger W, Hofer A, Legat FJ, Gruber-Wackernagel A, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol. 2011;165:640\u20135.","journal-title":"Br J Dermatol"},{"key":"1436_CR29","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jdv.12636","volume":"29","author":"JMPA Van Den Reek","year":"2015","unstructured":"Van Den Reek JMPA, Tummers M, Zweegers J, Seyger MMB, Van L\u00fcmig PPM, Driessen RJB, et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol. 2015;29:560\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1436_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10778.x","volume":"166","author":"JM Norlin","year":"2012","unstructured":"Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166:797\u2013802.","journal-title":"Br J Dermatol"},{"key":"1436_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bjd.13908","volume":"173","author":"IYK Iskandar","year":"2015","unstructured":"Iskandar IYK, Ashcroft DM, Warren RB, Yiu ZZN, McElhone K, Lunt M, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British association of dermatologists biologic interventions register. Br J Dermatol. 2015;173:510\u20138.","journal-title":"Br J Dermatol"},{"key":"1436_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2012.10996.x","volume":"167","author":"AM Oostveen","year":"2012","unstructured":"Oostveen AM, De Jager MEA, Van De Kerkhof PCM, Donders ART, De Jong EMGJ, Seyger MMB. The influence of treatments in daily clinical practice on the children\u2019s dermatology life quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol. 2012;167:145\u20139.","journal-title":"Br J Dermatol"},{"key":"1436_CR33","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961\u20139.","journal-title":"JAMA Dermatol"},{"key":"1436_CR34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/jdv.13634","volume":"30","author":"L Eissing","year":"2016","unstructured":"Eissing L, Rustenbach SJ, Krensel M, Zander N, Spehr C, Radtke MA, et al. Psoriasis registries worldwide: systematic overview on registry publications. J Eur Acad Dermatol Venereol. 2016;30:1100\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1436_CR35","unstructured":"Psoriasis Types, Symptoms & Causes | NIAMS [Internet]. [cited 2025 Feb 27]. Available from: https:\/\/www.niams.nih.gov\/health-topics\/psoriasis. Accessed Jan 2025."},{"key":"1436_CR36","first-page":"213","volume":"23","author":"MI Fatani","year":"2002","unstructured":"Fatani MI, Abdulghani MM, Al-Afif KA. Psoriasis in the eastern Saudi Arabia. Saudi Med J. 2002;23:213\u20137.","journal-title":"Saudi Med J"},{"key":"1436_CR37","doi-asserted-by":"publisher","first-page":"227990362211239","DOI":"10.1177\/22799036221123961","volume":"11","author":"HE Bayomy","year":"2022","unstructured":"Bayomy HE, Albedaiwi Y, Alabdulatif SKA, Almutairi FSF, Aloufi FAS, Alruwaili RHA, et al. Psoriasis in Northern Saudi Arabia: clinical features and implications for quality of life. J Public health Res. 2022;11:22799036221123960.","journal-title":"J Public health Res"},{"key":"1436_CR38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14907","author":"RS Alajmi","year":"2021","unstructured":"Alajmi RS, Alamoudi SM, Alabbasi AA, Alwagdani A, Alraddadi AA, Alamri A, et al. Patterns of comorbidities in psoriasis patients: a cross-sectional study. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.14907.","journal-title":"Cureus"},{"key":"1436_CR39","first-page":"114","volume":"8","author":"AA Alhumidi","year":"2013","unstructured":"Alhumidi AA. Retrospective 10 years review of 100 patients with psoriasis in the Kingdom of Saudi Arabia (KSA). Am J Res Commun. 2013;8:114\u201320.","journal-title":"Am J Res Commun"},{"key":"1436_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jssdds.2011.04.005","volume":"15","author":"SN Alsuwaidan","year":"2011","unstructured":"Alsuwaidan SN. Childhood psoriasis: analytic retrospective study in Saudi patients. J Saudi Soc Dermatol Dermatol Surg. 2011;15:57\u201361.","journal-title":"J Saudi Soc Dermatol Dermatol Surg"},{"key":"1436_CR41","first-page":"159","volume":"21","author":"AM Bhutto","year":"2011","unstructured":"Bhutto AM, Al-Ajlan AM, Al-Suwaidan SN. Characteristics and pattern of childhood psoriasis in Saudi Arabia. J Pakistan Assoc Dermatol. 2011;21:159\u201364.","journal-title":"J Pakistan Assoc Dermatol"},{"key":"1436_CR42","doi-asserted-by":"publisher","first-page":"E112","DOI":"10.1097\/JW9.0000000000000112","volume":"9","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Constantin MM, Dattola A, Hillary T, Kleyn E, Magnolo N. Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists. Int J Women\u2019s Dermatol. 2023;9:E112.","journal-title":"Int J Women\u2019s Dermatol"},{"key":"1436_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5281957","volume":"2020","author":"M Almohideb","year":"2020","unstructured":"Almohideb M. Epidemiological patterns of skin disease in Saudi Arabia: a systematic review and meta-analysis. Dermatol Res Pract. 2020;2020:1\u201312.","journal-title":"Dermatol Res Pract"},{"key":"1436_CR44","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4103\/sjhs.sjhs_180_19","volume":"9","author":"S Almutairi","year":"2020","unstructured":"Almutairi S, Alotaibi A, Almohideb M. Perception and assessment of psoriasis in the general population of Riyadh. Saudi Arabia Saudi J Heal Sci. 2020;9:102.","journal-title":"Saudi Arabia Saudi J Heal Sci"},{"issue":"Suppl","key":"1436_CR45","first-page":"3","volume":"13","author":"R Bissonnette","year":"2009","unstructured":"Bissonnette R, Searles G, Landells I, Shear NH, Papp K, Lui H, et al. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg. 2009;13(Suppl):3.","journal-title":"J Cutan Med Surg"},{"key":"1436_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2012.10.055","volume":"68","author":"AB Kimball","year":"2013","unstructured":"Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013;68:756\u201364.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR47","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet (London, England). 2008;371:1675\u201384.","journal-title":"Lancet (London, England)"},{"key":"1436_CR48","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet (London, England). 2008;371:1665\u201374.","journal-title":"Lancet (London, England)"},{"key":"1436_CR49","doi-asserted-by":"publisher","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","volume":"56","author":"A Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1-31.e115.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR50","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (London, England). 2005;366:1367\u201374.","journal-title":"Lancet (London, England)"},{"key":"1436_CR51","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"CL Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014\u201322.","journal-title":"N Engl J Med"},{"key":"1436_CR52","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-Cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004\u201313.","journal-title":"N Engl J Med"},{"key":"1436_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR54","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/COPD.S204391","volume":"14","author":"Y Lacasse","year":"2019","unstructured":"Lacasse Y, Krishnan J, Maltais F, Ekstr\u00f6m M. Patient registries for home oxygen research and evaluation. Int J Chron Obstruct Pulmon Dis. 2019;14:1299\u2013304.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1436_CR55","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545.","journal-title":"Rheum Dis Clin North Am"},{"key":"1436_CR56","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1346-8138.2011.01408.x","volume":"39","author":"H Takahashi","year":"2012","unstructured":"Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012;39:212\u20138.","journal-title":"J Dermatol"},{"key":"1436_CR58","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.clindermatol.2007.08.006","volume":"25","author":"E Christophers","year":"2007","unstructured":"Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529\u201334.","journal-title":"Clin Dermatol"},{"key":"1436_CR59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/gut.2009.199679","volume":"60","author":"CW Lees","year":"2011","unstructured":"Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739\u201353.","journal-title":"Gut"},{"key":"1436_CR60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","volume":"53","author":"S Madanagobalane","year":"2012","unstructured":"Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53:190\u20137.","journal-title":"Australas J Dermatol"},{"key":"1436_CR61","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827\u201336.","journal-title":"Gastroenterology"},{"key":"1436_CR62","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","volume":"51","author":"L Miele","year":"2009","unstructured":"Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778\u201386.","journal-title":"J Hepatol"},{"key":"1436_CR63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (London, England). 2006;367:29\u201335.","journal-title":"Lancet (London, England)"},{"key":"1436_CR64","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","volume":"63","author":"RG Langley","year":"2010","unstructured":"Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63:457\u201365.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR65","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1365-2133.2008.08727.x","volume":"159","author":"SR Feldman","year":"2008","unstructured":"Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159:704\u201310.","journal-title":"Br J Dermatol"},{"key":"1436_CR66","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","volume":"62","author":"A Menter","year":"2010","unstructured":"Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62:812\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR67","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"1436_CR68","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/archderm.141.12.1580","volume":"141","author":"C Fortes","year":"2005","unstructured":"Fortes C, Mastroeni S, Leffondr\u00e9 K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580\u20134.","journal-title":"Arch Dermatol"},{"key":"1436_CR69","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/ijd.ijd_420_23","volume":"68","author":"Y Manchanda","year":"2023","unstructured":"Manchanda Y, De A, Das S, Chakraborty D. Disease Assessment in Psoriasis. Indian J Dermatol. 2023;68:278\u201381.","journal-title":"Indian J Dermatol"},{"key":"1436_CR70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.det.2011.08.012","volume":"30","author":"K Li","year":"2012","unstructured":"Li K, Armstrong AW. A review of health outcomes in patients with psoriasis. Dermatol Clin. 2012;30:61\u201372.","journal-title":"Dermatol Clin"},{"key":"1436_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1436_CR72","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2340\/00015555-1456","volume":"93","author":"TM Ljosaa","year":"2013","unstructured":"Ljosaa TM, Stubhaug A, Mork C, Moum T, Wahl AK. Improvement in psoriasis area and severity index score predicts improvement in skin pain over time in patients with psoriasis. Acta Derm Venereol. 2013;93:330\u20134.","journal-title":"Acta Derm Venereol"},{"key":"1436_CR73","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/09546630600920041","volume":"17","author":"DJ Pearce","year":"2006","unstructured":"Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, et al. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat. 2006;17:288\u201393.","journal-title":"J Dermatolog Treat"},{"key":"1436_CR74","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jdin.2022.03.010","volume":"7","author":"C Learned","year":"2022","unstructured":"Learned C, Alsukait S, Deverapalli S, Elliott E, Moody K, Sobell J, et al. Psoriasis adverse events and associated medications as reported in the US Food and drug administration\u2019s adverse event reporting system from 2016 to 2021. JAAD Int. 2022;7:144.","journal-title":"JAAD Int"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01436-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01436-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:52:49Z","timestamp":1757170369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01436-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1436"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01436-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u201cError in \u2018Key Summary Points\u2019 updated\u201d","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohammad Ibrahim Fatani, Yousef Binamer, Hajer Y. Almudaiheem, Maysa Tariq Eshmawi, Fawaz Hamdi Aljehani, Sultanah Alshammari, Ahmed H. Al-Jedai have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The research was conducted following the ethical principles set out in the Declaration of Helsinki and approved by the institutional review board of the Saudi Ministry of Health (IRB Log No: 25-1 M). Due to the retrospective nature of the study, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}